<DOC>
	<DOCNO>NCT01435135</DOCNO>
	<brief_summary>The purpose study assess safety tolerability late boost regimen AIDSVAX B/E alone , ALVAC-HIV alone , ALVAC-HIV/AIDSVAX B/E combination HIV-uninfected participant RV 144 .</brief_summary>
	<brief_title>Study Late Boost Strategies HIV-uninfected Participants From Protocol RV 144</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<criteria>Must participate RV144 , receive active product , complete 4 vaccination visit per protocol . Must able understand complete inform consent process . Must successfully complete Test Understanding prior enrollment The volunteer must answer 80 % 8 10 question correctly include two compulsory question answer correctly . If volunteer unable , give two opportunity repeat TOU . If three attempt pass TOU volunteer still unable , volunteer become ineligible study participation . Must good general health without clinically significant medical history . HIVuninfected per predefined algorithm within 45 day enrollment . Laboratory screen analysis Hemoglobin : Women ≥12.0 g/dL . Men ≥12.5 g/dL White cell count : 4,000 11,000 cells/mm3 Platelets : 150,000 450,000/mm3 Normal liver function : ALT/AST ≤1.25 institutional upper limit reference range Creatinine : ≤1.25 institutional upper limit reference range Urinalysis ( dipstick ) blood protein great 1+ , glucose negative FemaleSpecific Criteria : Negative human choriogonadotropin ( βHCG ) pregnancy test ( urine ) woman prior vaccination ( day ) . Be use adequate birth control method 45 day prior first vaccine/placebo vaccination continue follow least 3 month final vaccine/placebo vaccination . Adequate birth control define follow : Contraceptive medication deliver orally , intramuscularly , vaginally , implant underneath skin , surgical method ( hysterectomy bilateral tubal ligation ) , condom , diaphragm , intrauterine device ( IUD ) , abstinence . 1 . Women breastfeed pregnant ( positive pregnancy test ) planning become pregnant window study enrollment 3 month last vaccination visit . History anaphylaxis serious adverse reaction vaccine include RV 144 vaccine , allergy reaction likely exacerbate component vaccine placebo , include egg , egg product , streptomycin , neomycin . Subject receive following substance : Chronic use therapy may modify immune response , IV immune globulin systemic corticosteroid ( dos &gt; 20 mg/day prednisone equivalent period exceed 10 day ) . The following exception permit exclude study participation : use corticosteroid nasal spray rhinitis , topical corticosteroid acute uncomplicated dermatitis ; short course ( duration 10 day less , single injection ) corticosteroid nonchronic condition ( base investigator clinical judgment ) least 2 week prior enrollment study . Blood product within 120 day prior HIV screen . Immunoglobulins within 14 day prior HIV screen . Any vaccine within 14 day prior initial study vaccine administration present study . Receipt investigational HIV vaccine product RV 144 regimen . Investigational research agent within 30 day prior initial study vaccine administration present study . Use antituberculosis prophylaxis therapy past 90 day . Any medical , psychiatric , social condition , occupational reason , responsibility , judgment investigator , contraindication protocol compliance impairs subject 's ability give inform consent . Psychiatric condition precludes compliance protocol ; past present psychosis ; past present bipolar disorder ; disorder require lithium ; within 5 year prior enrollment , history suicide plan attempt . Study site employee involve protocol and/or may direct access study related area .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>